Royalty Pharma plc reported third‑quarter 2025 results that surpassed analyst expectations, with earnings per share of $1.17 versus the consensus estimate of $1.11—a $0.06 or 5.4% beat. The company’s revenue rose to $814 million, outpacing the $803.28 million estimate by $10.72 million, a 1.3% lift. The earnings beat was driven by disciplined cost management and a favorable mix of high‑margin royalty agreements, while the revenue gain reflected continued strong demand for its core assets, including the cystic fibrosis franchise, Tremfya, and Voranigo.
Continue reading for full analysis...
Royalty Pharma plc purchased a 1 % royalty interest in Alnylam Pharmaceuticals’ RNAi therapeutic AMVUTTRA from Blackstone Life Sciences for $310 million. The royalty covers worldwide net sales of AMVUTTRA through March 2035, with payments beginning October 1 2025.
Continue reading for full analysis...